Dejerine-Sottas Disease
Also known as: Hereditary Motor and Sensory Neuropathy Type 3, HMSN III, Congenital Hypomyelinating Neuropathy
Dejerine-Sottas disease (DSD) is a rare, inherited neurological disorder characterized by progressive muscle weakness and sensory loss, typically beginning in infancy or early childhood. It is a severe form of hereditary motor and sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth disease. DSD results from demyelination and axonal degeneration of peripheral nerves, leading to impaired motor and sensory function.
Dejerine-Sottas disease is a rare condition where your muscles get weak and you have trouble feeling things, starting when you're a baby. It's like your body's wires (nerves) aren't working right, making it hard to move and feel.
Signs & Symptoms
- Delayed motor milestones
- Progressive muscle weakness
- Sensory loss (numbness, tingling)
- Hypotonia (decreased muscle tone)
- Areflexia (absent reflexes)
- Skeletal deformities (scoliosis, foot deformities)
- Tremors
- Nystagmus
- Pupillary abnormalities
- Thickened peripheral nerves (palpable)
- Hearing loss
Treatment Options
Physical Therapy
SUPPORTIVEOccupational Therapy
SUPPORTIVEOrthotics and Assistive Devices
SUPPORTIVEPain Management
MODERATELY EFFECTIVESurgical Correction of Skeletal Deformities
MODERATELY EFFECTIVEDiagnosis
- Clinical examination
- Electrophysiological studies (nerve conduction velocity, electromyography)
- Nerve biopsy
- Genetic testing
History
Dejerine-Sottas disease was first described by Joseph Dejerine and Jules Sottas in 1893. They reported on two siblings with progressive motor and sensory neuropathy, characterized by thickened peripheral nerves and early onset.
Recent Breakthroughs
Gene Therapy Research for CMT
Early-stage research is exploring gene therapy approaches for various forms of Charcot-Marie-Tooth disease, including subtypes associated with Dejerine-Sottas disease. These therapies aim to correct the underlying genetic defects causing nerve damage.
Advancements in Understanding Disease Mechanisms
Ongoing research continues to elucidate the molecular mechanisms underlying demyelination and axonal degeneration in DSD, identifying potential therapeutic targets.